Skip to main content
SpringerLink
Log in

Clinical and Prognostic Significance of Non-criteria Antiphospholipid Antibody Tests

  • Chapter
  • First Online:
Antiphospholipid Syndrome

Abstract

Classification criteria for antiphospholipid syndrome (APS) require IgG and IgM isotypes of the anticardiolipin antibodies (aCL), anti-β2 glycoprotein I antibodies (aβ2GPI), and/or the lupus anticoagulant (LA) to satisfy the laboratory criterion for disease definition. However, over the past 20 years, several other non-criteria antiphospholipid antibodies (aPL) directed to other proteins of the coagulation cascade (i.e., prothrombin and/or phosphatidylserine–prothrombin complex), to some domains of β2GPI, or to the anticoagulant activity of annexin A5, have been proposed. The Laboratory Diagnostics Task Force at the 14th International Congress on aPL (Rio de Janeiro, Brazil, 2013) highlighted several non-criteria assays. However, there was consensus that further studies are necessary to obtain high-quality evidence defining their role as risk predictors. The task force reviewed the literature and conducted new studies between 2013 and 2016; the conclusions were presented at a special session during the 15th International Congress on aPL (www.apsistanbul2016.org, North Cyprus, September 2016). This paper updates our recommendations.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295–306.

    Article  CAS  PubMed  Google Scholar 

  2. Bertolaccini ML, Hughes GR, Khamashta MA. Revisiting antiphospholipid antibodies: from targeting phospholipids to phospholipid binding proteins. Clin Lab. 2004;50:653–65.

    CAS  PubMed  Google Scholar 

  3. Bertolaccini ML, Amengual O, Andreoli L, et al. 14th international congress on antiphospholipid antibodies task force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmun Rev. 2014;13:917–30.

    Article  PubMed  Google Scholar 

  4. Bertolaccini ML, Amengual O, Atsumi T, et al. ‘Non-criteria’ aPL tests: report of a task force and preconference workshop at the 13th international congress on antiphospholipid antibodies, Galveston, TX, USA, April 2010. Lupus. 2011;20:191–205.

    Article  CAS  PubMed  Google Scholar 

  5. Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML. Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review. Thromb Haemost. 2014;111:354–64.

    Article  CAS  PubMed  Google Scholar 

  6. Amengual O, Forastiero R, Sugiura-Ogasawara M, et al. Evaluation of phosphatidylserine-dependent antiprothrombin antibody testing for the diagnosis of antiphospholipid syndrome: results of an international multicentre study. Lupus. 2016;26:266–76.

    Article  PubMed  Google Scholar 

  7. Hughes GR, Khamashta MA. Seronegative antiphospholipid syndrome. Ann Rheum Dis. 2003;62:1127.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Giannakopoulos B, Krilis SA. The pathogenesis of the antiphospholipid syndrome. N Engl J Med. 2013;368:1033–44.

    Article  CAS  PubMed  Google Scholar 

  9. Meroni PL, Borghi MO, Raschi E, Tedesco F. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol. 2011;7:330–9.

    Article  CAS  PubMed  Google Scholar 

  10. Meroni PL, Chighizola CB, Rovelli F, Gerosa M. Antiphospholipid syndrome in 2014: more clinical manifestations, novel pathogenic players and emerging biomarkers. Arthritis Res Ther. 2014;16:209.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Chighizola CB, Raschi E, Borghi MO, Meroni PL. Update on the pathogenesis and treatment of the antiphospholipid syndrome. Curr Opin Rheumatol. 2015;27:476–82.

    Article  CAS  PubMed  Google Scholar 

  12. Iverson GM, Reddel S, Victoria EJ, et al. Use of single point mutations in domain I of beta 2-glycoprotein I to determine fine antigenic specificity of antiphospholipid autoantibodies. J Immunol. 2002;169:7097–103.

    Article  CAS  PubMed  Google Scholar 

  13. de Laat B, Derksen RH, Urbanus RT, de Groot PG. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood. 2005;105:1540–5.

    Article  PubMed  Google Scholar 

  14. de Laat B, Pengo V, Pabinger I, et al. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost. 2009;7:1767–73.

    Article  PubMed  Google Scholar 

  15. Shoenfeld Y, Krause I, Kvapil F, et al. Prevalence and clinical correlations of antibodies against six beta2-glycoprotein-I-related peptides in the antiphospholipid syndrome. J Clin Immunol. 2003;23:377–83.

    Article  CAS  PubMed  Google Scholar 

  16. Arvieux J, Regnault V, Hachulla E, Darnige L, Roussel B, Bensa JC. Heterogeneity and immunochemical properties of anti-beta2-glycoprotein I autoantibodies. Thromb Haemost. 1998;80:393–8.

    CAS  PubMed  Google Scholar 

  17. de Laat B, Derksen RH, van Lummel M, Pennings MT, de Groot PG. Pathogenic anti-beta2-glycoprotein I antibodies recognize domain I of beta2-glycoprotein I only after a conformational change. Blood. 2006;107:1916–24.

    Article  PubMed  Google Scholar 

  18. Agostinis C, Durigutto P, Sblattero D, et al. A non complement-fixing antibody to beta2 glycoprotein I as a novel therapy to control abortions and thrombosis in antiphospholipid syndrome. Blood. 2014;123:3478–87.

    Article  CAS  PubMed  Google Scholar 

  19. Pericleous C, Ruiz-Limon P, Romay-Penabad Z, et al. Proof-of-concept study demonstrating the pathogenicity of affinity-purified IgG antibodies directed to domain I of beta2-glycoprotein I in a mouse model of anti-phospholipid antibody-induced thrombosis. Rheumatology (Oxford). 2015;54:722–7.

    Article  Google Scholar 

  20. Ioannou Y, Romay-Penabad Z, Pericleous C, et al. In vivo inhibition of antiphospholipid antibody-induced pathogenicity utilizing the antigenic target peptide domain I of beta2-glycoprotein I: proof of concept. J Thromb Haemost. 2009;7:833–42.

    Article  CAS  PubMed  Google Scholar 

  21. Pelkmans L, Kelchtermans H, de Groot PG, et al. Variability in exposure of epitope G40-R43 of domain i in commercial anti-beta2-glycoprotein I IgG ELISAs. PLoS One. 2013;8:e71402.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Agar C, van Os GM, Morgelin M, et al. Beta2-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome. Blood. 2010;116:1336–43.

    Article  CAS  PubMed  Google Scholar 

  23. Andreoli L, Chighizola CB, Nalli C, et al. Clinical characterization of antiphospholipid syndrome by detection of IgG antibodies against beta2 -glycoprotein I domain 1 and domain 4/5: ratio of anti-domain 1 to anti-domain 4/5 as a useful new biomarker for antiphospholipid syndrome. Arthritis Rheumatol. 2015;67:2196–204.

    Article  CAS  PubMed  Google Scholar 

  24. Andreoli L, Nalli C, Motta M, et al. Anti-beta(2)-glycoprotein I IgG antibodies from 1-year-old healthy children born to mothers with systemic autoimmune diseases preferentially target domain 4/5: might it be the reason for their ‘innocent’ profile? Ann Rheum Dis. 2011;70:380–3.

    Article  CAS  PubMed  Google Scholar 

  25. Chighizola CB, Andreoli L, Tonello M, et al. The clinical relevance of antibodies against domain 1 and domain 4/5 of β2 glycoprotein I in obstetric antiphospholipid syndrome. Lupus. 2016;25:13. OP21

    Google Scholar 

  26. Gharavi AE, Harris EN, Asherson RA, Hughes GR. Anticardiolipin antibodies: isotype distribution and phospholipid specificity. Ann Rheum Dis. 1987;46:1–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Weidmann CE, Wallace DJ, Peter JB, Knight PJ, Bear MB, Klinenberg JR. Studies of IgG, IgM and IgA antiphospholipid antibody isotypes in systemic lupus erythematosus. J Rheumatol. 1988;15:74–9.

    CAS  PubMed  Google Scholar 

  28. Kalunian KC, Peter JB, Middlekauff HR, et al. Clinical significance of a single test for anti-cardiolipin antibodies in patients with systemic lupus erythematosus. Am J Med. 1988;85:602–8.

    Article  CAS  PubMed  Google Scholar 

  29. Alarcon-Segovia D, Deleze M, Oria CV, et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients. Medicine (Baltimore). 1989;68:353–65.

    Article  CAS  Google Scholar 

  30. Fanopoulos D, Teodorescu MR, Varga J, Teodorescu M. High frequency of abnormal levels of IgA anti-beta2-glycoprotein I antibodies in patients with systemic lupus erythematosus: relationship with antiphospholipid syndrome. J Rheumatol. 1998;25:675–80.

    CAS  PubMed  Google Scholar 

  31. Tsutsumi A, Matsuura E, Ichikawa K, et al. Antibodies to beta 2-glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus. Arthritis Rheum. 1996;39:1466–74.

    Article  CAS  PubMed  Google Scholar 

  32. Cucurull E, Gharavi AE, Diri E, Mendez E, Kapoor D, Espinoza LR. IgA anticardiolipin and anti-beta2-glycoprotein I are the most prevalent isotypes in African American patients with systemic lupus erythematosus. Am J Med Sci. 1999;318:55–60.

    CAS  PubMed  Google Scholar 

  33. Lakos G, Kiss E, Regeczy N, et al. Isotype distribution and clinical relevance of anti-beta2-glycoprotein I (beta2-GPI) antibodies: importance of IgA isotype. Clin Exp Immunol. 1999;117:574–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Greco TP, Amos MD, Conti-Kelly AM, Naranjo JD, Ijdo JW. Testing for the antiphospholipid syndrome: importance of IgA anti-beta 2-glycoprotein I. Lupus. 2000;9:33–41.

    Article  CAS  PubMed  Google Scholar 

  35. Pierangeli SS, Liu XW, Barker JH, Anderson G, Harris EN. Induction of thrombosis in a mouse model by IgG, IgM and IgA immunoglobulins from patients with the antiphospholipid syndrome. Thromb Haemost. 1995;74:1361–7.

    CAS  PubMed  Google Scholar 

  36. Ruiz-Limon P, Romay-Penabad Z, Carrera-Marin AL, Papalardo E, Pierangeli SS. IgA anti-β2glycoprotein I antibodies are pathogenic in a mouse model of APS. Arthritis Rheum. 2012;64:S742. (abstract)

    Google Scholar 

  37. Nalli C, Rodrigues M, Balestrieri E, et al. Utility of additional antibody tests in the profile risk stratification of patients with antiphospholipid syndrome. Lupus. 2016;25:PP033.

    Google Scholar 

  38. Tebo AE, Jaskowski TD, Willis R, Branch DW, Petri M. Persistence of IgA antibodies to β2Glycoprotein I in patients with systemic lupus erythematosus. Lupus. 2016;25:PP022.

    Google Scholar 

  39. Tortosa C, Martinez-Flores JA, Serrano M, et al. Isolated IgA anti-β2-glycoprotein I in patients with no history of antiphospholipid syndrome (APS)-related symptomatology as a risk factor for the occurrence of APS events in a period of five years. Lupus. 2016;25:PP021.

    Google Scholar 

  40. Harris EN, Pierangeli SS. A more specific assay for the detection of antiphospholipid. Clin Immunol Newsletter. 1995;15:26–8.

    Article  Google Scholar 

  41. Harris EN, Gharavi AE, Wasley GD, Hughes GR. Use of an enzyme-linked immunosorbent assay and of inhibition studies to distinguish between antibodies to cardiolipin from patients with syphilis or autoimmune disorders. J Infect Dis. 1988;157:23–31.

    Article  CAS  PubMed  Google Scholar 

  42. Merkel PA, Chang Y, Pierangeli SS, Harris EN, Polisson RP. Comparison between the standard anticardiolipin antibody test and a new phospholipid test in patients with connective tissue diseases. J Rheumatol. 1999;26:591–6.

    CAS  PubMed  Google Scholar 

  43. Pierangeli SS, Silva LK, Harris EN. A flow cytometric assay for the detection of antiphospholipid antibodies. Am Clin Lab. 1999;18:18–9.

    CAS  PubMed  Google Scholar 

  44. Pierangeli SS, Gharavi AE, Harris EN. Testing for antiphospholipid antibodies: problems and solutions. Clin Obstet Gynecol. 2001;44:48–57.

    Article  CAS  PubMed  Google Scholar 

  45. Smikle M, Wharfe G, Fletcher H, et al. Anticardiolipin, other antiphospholipid antibody tests and diagnosis of the antiphospholipid syndrome. Hum Antibodies. 2003;12:63–6.

    CAS  PubMed  Google Scholar 

  46. Budd R, Harley E, Quarshie A, Henderson V, Harris EN, Pierangeli SS. A re-appraisal of the normal cut-off assignment for anticardiolipin IgM tests. J Thromb Haemost. 2006;4:2210–4.

    Article  CAS  PubMed  Google Scholar 

  47. Suh-Lailam BB, Cromar A, Davis KW, Tebo AE. APhL antibody ELISA as an alternative to anticardiolipin test for the diagnosis of antiphospholipid syndrome. Int J Clin Exp Pathol. 2012;5:210–5.

    CAS  PubMed  PubMed Central  Google Scholar 

  48. Pierangeli SS, Harris EN. Advances in antiphospholipid antibody testing. Clin Appl Immunol Rev. 2000;1:59–72.

    Article  CAS  Google Scholar 

  49. Forastiero R, Papalardo E, Watkins M, et al. Evaluation of different immunoassays for the detection of antiphospholipid antibodies: report of a wet workshop during the 13th international congress on antiphospholipid antibodies. Clin Chim Acta. 2014;428:99–105.

    Article  CAS  PubMed  Google Scholar 

  50. Zuo Y, Willis R, Papalardo E, et al. A unique antiphospholipid assay recognizing phospholipid mixture compared with criteria antiphospholipid immunoassays in lupus patients. Lupus. 2016. pii: 0961203316671812. [Epub ahead of print].

    Google Scholar 

  51. Willis R, Schleh A, Pierangeli SS, Harris EN. Superior performance of a mixed antigen (phosphatidyl serine/phosphatidic acid/B2GP1) ELISA APHL assay compared to conventional anticardiolipin/B2GPI and anti-B2GPI assays in APS patients. Lupus. 2016;25:PP028.

    Google Scholar 

  52. Lu CS, Horizon AA, Hwang KK, et al. Identification of polyclonal and monoclonal antibodies against tissue plasminogen activator in the antiphospholipid syndrome. Arthritis Rheum. 2005;52:4018–27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Lin WS, Chen PC, Yang CD, et al. Some antiphospholipid antibodies recognize conformational epitopes shared by beta2-glycoprotein I and the homologous catalytic domains of several serine proteases. Arthritis Rheum. 2007;56:1638–47.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Hwang KK, Grossman JM, Visvanathan S, et al. Identification of anti-thrombin antibodies in the antiphospholipid syndrome that interfere with the inactivation of thrombin by antithrombin. J Immunol. 2001;167:7192–8.

    Article  CAS  PubMed  Google Scholar 

  55. Yang YH, Chien D, Wu M, et al. Novel autoantibodies against the activated coagulation factor IX (FIXa) in the antiphospholipid syndrome that interpose the FIXa regulation by antithrombin. J Immunol. 2009;182:1674–80.

    Article  CAS  PubMed  Google Scholar 

  56. Yang YH, Hwang KK, FitzGerald J, et al. Antibodies against the activated coagulation factor X (FXa) in the antiphospholipid syndrome that interfere with the FXa inactivation by antithrombin. J Immunol. 2006;177:8219–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Yang CD, Hwang KK, Yan W, et al. Identification of anti-plasmin antibodies in the antiphospholipid syndrome that inhibit degradation of fibrin. J Immunol. 2004;172:5765–73.

    Article  CAS  PubMed  Google Scholar 

  58. Hwang KK, Yang CD, Yan W, Grossman JM, Hahn BH, Chen PP. A thrombin-cross-reactive anticardiolipin antibody binds to and inhibits the anticoagulant function of activated protein C. Arthritis Rheum. 2003;48:1622–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Shebuski RJ, Kilgore KS. Role of inflammatory mediators in thrombogenesis. J Pharmacol Exp Ther. 2002;300:729–35.

    Article  CAS  PubMed  Google Scholar 

  60. Artim-Esen B, Pericleous C, Mackie I, et al. Anti-factor Xa antibodies in patients with antiphospholipid syndrome and their effects upon coagulation assays. Arthritis Res Ther. 2015;17:47.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Redecha P, Tilley R, Tencati M, et al. Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury. Blood. 2007;110:2423–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Gerke V, Moss SE. Annexins: from structure to function. Physiol Rev. 2002;82:331–71.

    Article  CAS  PubMed  Google Scholar 

  63. Mortimer JC, Laohavisit A, Macpherson N, et al. Annexins: multifunctional components of growth and adaptation. J Exp Bot. 2008;59:533–44.

    Article  CAS  PubMed  Google Scholar 

  64. Tait JF, Sakata M, McMullen BA, et al. Placental anticoagulant proteins: isolation and comparative characterization four members of the lipocortin family. Biochemistry. 1988;27:6268–76.

    Article  CAS  PubMed  Google Scholar 

  65. Wu XX, Pierangeli SS, Rand JH. Resistance to annexin A5 binding and anticoagulant activity in plasmas from patients with the antiphospholipid syndrome but not with syphilis. J Thromb Haemost. 2006;4:271–3.

    Article  CAS  PubMed  Google Scholar 

  66. Rand JH, Wu XX, Lapinski R, et al. Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome. Blood. 2004;104:2783–90.

    Article  CAS  PubMed  Google Scholar 

  67. Hunt BJ, Wu XX, de Laat B, Arslan AA, Stuart-Smith S, Rand JH. Resistance to annexin A5 anticoagulant activity in women with histories for obstetric antiphospholipid syndrome. Am J Obstet Gynecol. 2011;205:485. e17–23

    Article  PubMed  PubMed Central  Google Scholar 

  68. Wahezi DM, Ilowite NT, Wu XX, et al. Annexin A5 anticoagulant activity in children with systemic lupus erythematosus and the association with antibodies to domain I of beta2-glycoprotein I. Lupus. 2013;22:702–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Wahezi DM, Ilowite NT, Rajpathak S, Rand JH. Prevalence of annexin A5 resistance in children and adolescents with rheumatic diseases. J Rheumatol. 2012;39:382–8.

    Article  CAS  PubMed  Google Scholar 

  70. de Laat B, Wu XX, van Lummel M, Derksen RH, de Groot PG, Rand JH. Correlation between antiphospholipid antibodies that recognize domain I of beta2-glycoprotein I and a reduction in the anticoagulant activity of annexin A5. Blood. 2007;109:1490–4.

    Article  PubMed  Google Scholar 

  71. Hemker HC, Beguin S. Phenotyping the clotting system. Thromb Haemost. 2000;84:747–51.

    CAS  PubMed  Google Scholar 

  72. Hemker HC, Giesen PL, Ramjee M, Wagenvoord R, Beguin S. The thrombogram: monitoring thrombin generation in platelet-rich plasma. Thromb Haemost. 2000;83:589–91.

    CAS  PubMed  Google Scholar 

  73. Regnault V, Beguin S, Wahl D, de Maistre E, Coenraad Hemker H, Lecompte T. Thrombinography shows acquired resistance to activated protein C in patients with lupus anticoagulants. Thromb Haemost. 2003;89:208–12.

    CAS  PubMed  Google Scholar 

  74. Wahl D, Membre A, Perret-Guillaume C, Regnault V, Lecompte T. Mechanisms of antiphospholipid-induced thrombosis: effects on the protein C system. Curr Rheumatol Rep. 2009;11:77–81.

    Article  CAS  PubMed  Google Scholar 

  75. Cohen H, Hunt BJ, Efthymiou M, et al. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial. Lancet Haematol. 2016;3:e426–36.

    Article  PubMed  PubMed Central  Google Scholar 

  76. Devreese K, Peerlinck K, Hoylaerts MF. Thrombotic risk assessment in the antiphospholipid syndrome requires more than the quantification of lupus anticoagulants. Blood. 2010;115:870–8.

    Article  CAS  PubMed  Google Scholar 

  77. Lecompte T, Wahl D, Perret-Guillaume C, Hemker HC, Lacolley P, Regnault V. Hypercoagulability resulting from opposite effects of lupus anticoagulants is associated strongly with thrombotic risk. Haematologica. 2007;92:714–5.

    Article  PubMed  Google Scholar 

  78. van Wijnen M, Stam JG, van’t Veer C, et al. The interaction of protein S with the phospholipid surface is essential for the activated protein C-independent activity of protein S. Thromb Haemost. 1996;76:397–403.

    PubMed  Google Scholar 

  79. Crowther MA, Johnston M, Weitz J, Ginsberg JS. Free protein S deficiency may be found in patients with antiphospholipid antibodies who do not have systemic lupus erythematosus. Thromb Haemost. 1996;76:689–91.

    CAS  PubMed  Google Scholar 

  80. Zuily S, Regnault V, Guillemin F, et al. Superficial vein thrombosis, thrombin generation and activated protein C resistance as predictors of thromboembolic events in lupus and antiphospholipid patients. A prospective cohort study. Thromb Res. 2013;132:e1–7.

    Article  CAS  PubMed  Google Scholar 

  81. Pengo V, Tripodi A, Reber G, et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2009;7:1737–40.

    Article  CAS  PubMed  Google Scholar 

  82. Devreese KM, Pierangeli SS, de Laat B, et al. Testing for antiphospholipid antibodies with solid phase assays: guidance from the SSC of the ISTH. J Thromb Haemost. 2014;12:792–5.

    Article  CAS  PubMed  Google Scholar 

  83. Van Hoecke F, Persijn L, Decavele AS, Devreese K. Performance of two new, automated chemiluminescence assay panels for anticardiolipin and anti-beta2-glycoprotein I antibodies in the laboratory diagnosis of the antiphospholipid syndrome. Int J Lab Hematol. 2012;34:630–40.

    Article  PubMed  Google Scholar 

  84. de Moerloose P, Reber G, Musial J, Arnout J. Analytical and clinical performance of a new, automated assay panel for the diagnosis of antiphospholipid syndrome. J Thromb Haemost. 2010;8:1540–6.

    Article  Google Scholar 

  85. Oku K, Amengual O, Kato M, et al. Significance of fully automated tests for the diagnosis of antiphospholipid syndrome. Thromb Res. 2016;146:1–6.

    Article  CAS  PubMed  Google Scholar 

  86. Devreese KM, Poncet A, Lindhoff-Last E, Musial J, de Moerloose P, Fontana P. A multicenter study to assess the reproducibility of antiphospholipid antibody results produced by an automated system. J Thromb Haemost. 2017;15:91–5.

    Google Scholar 

  87. Devreese K, Peerlinck K, Hoylaerts MF. Diagnostic test combinations associated with thrombosis in lupus anticoagulant positive patients. Thromb Haemost. 2011;105:736–8.

    Article  CAS  PubMed  Google Scholar 

  88. Kelchtermans H, Pelkmans L, de Laat B, Devreese KM. IgG/IgM antiphospholipid antibodies present in the classification criteria for the antiphospholipid syndrome: a critical review of their association with thrombosis. J Thromb Haemost. 2016;14:1530–48.

    Article  CAS  PubMed  Google Scholar 

  89. Pericleous C, Ferreira I, Borghi O, et al. Measuring IgA anti-beta2-glycoprotein I and IgG/IgA anti-domain I antibodies adds value to current serological assays for the antiphospholipid syndrome. PLoS One. 2016;11:e0156407.

    Article  PubMed  PubMed Central  Google Scholar 

  90. Chighizola CB, Gerosa M, Meroni PL. New tests to detect antiphospholipid antibodies: anti-domain I beta-2-glycoprotein-I antibodies. Curr Rheumatol Rep. 2014;16:402.

    Article  PubMed  Google Scholar 

  91. Mahler M, Albesa R, Zohoury N, et al. Autoantibodies to domain 1 of beta 2 glycoprotein I determined using a novel chemiluminescence immunoassay demonstrate association with thrombosis in patients with antiphospholipid syndrome. Lupus. 2016;25:911–6.

    Article  CAS  PubMed  Google Scholar 

  92. De Craemer AS, Musial J, Devreese KM. Role of anti-domain 1-beta2 glycoprotein I antibodies in the diagnosis and risk stratification of antiphospholipid syndrome. J Thromb Haemost. 2016;14:1779–87.

    Article  PubMed  Google Scholar 

  93. Pengo V, Ruffatti A, Tonello M, et al. Antiphospholipid syndrome: antibodies to domain 1 of beta2-glycoprotein 1 correctly classify patients at risk. J Thromb Haemost. 2015;13:782–7.

    Article  CAS  PubMed  Google Scholar 

  94. Meneghel L, Ruffatti A, Gavasso S, et al. Detection of IgG anti-domain I beta2 glycoprotein I antibodies by chemiluminescence immunoassay in primary antiphospholipid syndrome. Clin Chim Acta. 2015;446:201–5.

    Article  CAS  PubMed  Google Scholar 

  95. Mondejar R, Gonzalez-Rodriguez C, Toyos-Saenz de Miera FJ, et al. Role of antiphospholipid score and anti-beta2-glycoprotein I domain I autoantibodies in the diagnosis of antiphospholipid syndrome. Clin Chim Acta. 2014;431:174–8.

    Article  CAS  PubMed  Google Scholar 

  96. Zhang S, Wu Z, Chen S, et al. Evaluation of the diagnostic potential of antibodies to beta2-glycoprotein 1 domain 1 in Chinese patients with antiphospholipid syndrome. Sci Rep. 2016;6:23839.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  97. Zhang S, Wu Z, Zhang F, Li Y. Role of anti-domain 1- beta2 glycoprotein I antibodies in the diagnosis and risk stratification of antiphospholipid syndrome: comment. J Thromb Haemost. 2016;14:2076–8.

    Article  CAS  PubMed  Google Scholar 

  98. Devreese K, Kelchtermans H, de Laat B. Differences in sensitivity of two automated panels for anticardiolipin and anti-beta2glycoprotein I antibodies in the laboratory diagnosis of antiphospholipid syndrome due to the exposure of the domain I epitope of beta2glycoprotein I on the solid phase. J Thromb Haemost. 2014;12:55.

    Article  Google Scholar 

  99. De Craemer AS, Devreese KM. Role of anti-domain 1-beta2 glycoprotein I antibodies in the diagnosis and risk stratification of antiphospholipid syndrome: reply. J Thromb Haemost. 2016;14:2078–80.

    Article  PubMed  Google Scholar 

  100. Devreese K, Hoylaerts MF. Challenges in the diagnosis of the antiphospholipid syndrome. Clin Chem. 2010;56:930–40.

    Article  CAS  PubMed  Google Scholar 

  101. Rodriguez-Garcia V, Ioannou Y, Fernandez-Nebro A, Isenberg DA, Giles IP. Examining the prevalence of non-criteria anti-phospholipid antibodies in patients with anti-phospholipid syndrome: a systematic review. Rheumatology (Oxford). 2015;54:2042–50.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Academic Department of Vascular Surgery, Cardiovascular Division, King’s College London, St Thomas’ Hospital, London, UK

    Maria Laura Bertolaccini

  2. Spedali Civili, Brescia, Italy, Clinical and Experimental Sciences- Rheumatology and Clinical Immunology Unit, Brescia, Italy

    Angela Tincani

  3. Department of Clinical Sciences and Community Health, Experimental Laboratory of Immunorheumatolgy, University of Milan, IRCCS Istituto Auxologico Italiano, Cusano Milanino (Mi), Italy

    Maria Orietta Borghi

  4. Centre for Rheumatology Research, Division of Medicine, University College London Hospitals, London, UK

    Anisur Rahman

  5. Department of Pathology & Lab Medicine, Weill Cornell Medical College, New York & Presbyterian Hospital, New York, NY, USA

    Jacob Rand

  6. Faculty of Medicine, Inserm U1116, Vandoeuvre-les-Nancy, France

    Véronique Regnault

  7. Spedali Civili, Clinical and Experimental Sciences, Rheumatology and Clinical Immunology Unit, Brescia, Italy

    Rajesh Kumar

  8. Department of Cardio-Vascular Medicine, Vascular Medicine Division and Regional Competence Center For Rare Vascular And Systemic Autoimmune Diseases, Insitut Lorrain du Coeur et des Vaisseaux, Nancy University Hospital, Vandoeuvre-lès-Nancy Cedex, France

    Denis Wahl

  9. Internal Medicine, Rheumatology Division, University of Texas Medical Branch, Galveston, TX, USA

    Rohan Willis

  10. Vascular Medicine Division and Regional Competence Centre For Rare Vascular And Systemic Autoimmune Diseases, Nancy University Hospital, Vandoeuvre-lès-Nancy Cedex, France

    Stéphane Zuily

  11. Guy’s and St Thomas’ NHS Foundation Trust, Louise Coote Lupus Unit, Rheumatology Department, Guy’s Hospital, London, UK

    Giovanni Sanna

  12. Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, Japan

    Olga Amengual

  13. Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul, Turkey

    Bahar Artim-Eser

  14. Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, Japan

    Tatsuya Atsumi

  15. Synapse Research Institute, Maastricht, The Netherlands

    Philip G. de Groot

  16. Department of Biochemistry, Maastricht University Medical Centre, Maastricht, Limburg, Netherlands

    Bas de Laat

  17. Coagulation Laboratory, Department of Clinical Chemistry, Microbiology and Immunology, Ghent University Hospital, Ghent, Belgium

    Katrien M. J. Devreese

  18. Centre for Rheumatology Research, UCL Division of Medicine, University College London Hospital, London, UK

    Ian Giles

  19. ASST-G. Pini and Immuno-Rheumatology Research Laboratory Istituto Auxologico Italiano, Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy

    Pier Luigi Meroni

Authors
  1. Maria Laura Bertolaccini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Olga Amengual
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bahar Artim-Eser
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tatsuya Atsumi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Philip G. de Groot
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Bas de Laat
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Katrien M. J. Devreese
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ian Giles
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Pier Luigi Meroni
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Maria Orietta Borghi
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Anisur Rahman
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Jacob Rand
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Véronique Regnault
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Rajesh Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Angela Tincani
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Denis Wahl
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Rohan Willis
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Stéphane Zuily
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Giovanni Sanna
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Maria Laura Bertolaccini or Véronique Regnault .

Editor information

Editors and Affiliations

  1. The Barbara Volcker Center for Women and Rheumatic Diseases, Associate Attending Physician, Hospital for Special Surgery, Associate Professor of Medicine, Weill Cornell Medicine, New York, New York, USA

    Doruk Erkan

  2. The Barbara Volcker Center for Women and Rheumatic Diseases, Attending Physician, Hospital for Special Surgery, Professor of Medicine and Obstetrics-Gynecology, Weill Cornell Medicine, New York, New York, USA

    Michael D. Lockshin

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Bertolaccini, M.L. et al. (2017). Clinical and Prognostic Significance of Non-criteria Antiphospholipid Antibody Tests. In: Erkan, D., Lockshin, M. (eds) Antiphospholipid Syndrome. Springer, Cham. https://doi.org/10.1007/978-3-319-55442-6_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-55442-6_8

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-55440-2

  • Online ISBN: 978-3-319-55442-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation